{"entity":{"id":"mds-lower-risk","kind":"cancer","name":"Lower-risk myelodysplastic syndromes","aka":["Low-risk MDS","IPSS-R very low, low and intermediate MDS","Lower-risk myelodysplastic neoplasms","Transfusion-dependent lower-risk MDS"],"tldr":"Lower-risk myelodysplastic syndromes rarely turn into leukaemia quickly; the problem is anaemia and the transfusions it demands. Erythropoietin, then luspatercept (COMMANDS) and the telomerase blocker imetelstat (IMerge), free many patients from transfusions for months or years, and lenalidomide does the same for the del(5q) subtype.","summary":"Risk in myelodysplastic syndromes is scored by IPSS-R (blasts, cytogenetics and depth of cytopenias) and now IPSS-M, which adds mutations such as SF3B1 (favourable) and TP53 (adverse). Very low, low and intermediate IPSS-R groups, or IPSS-M low and moderate-low, are lower risk: median survival is measured in years and leukaemic transformation is uncommon, so treatment aims at the cytopenias and their consequences, chiefly transfusion-dependent anaemia with iron overload, and at quality of life. Watchful waiting is right for patients without symptoms.\n\nAnaemia treatment is stepwise. Erythropoiesis-stimulating agents help around half of patients with a serum erythropoietin below 500 U/L. Lenalidomide gives transfusion independence to most patients with del(5q). Luspatercept, a TGF-beta superfamily ligand trap that releases late-stage red cell maturation, was approved in 2020 after MEDALIST for ring-sideroblast disease after erythropoietin failure, and COMMANDS (2023) moved it to first line: 58.5 percent of transfusion-dependent, erythropoietin-naive patients became transfusion independent for at least 12 weeks with a haemoglobin rise, against 31.2 percent on epoetin alfa. Imetelstat, the first telomerase inhibitor, was approved in 2024 after IMerge: in erythropoietin-refractory patients, 39.8 percent became transfusion independent for eight weeks and 28 percent for 24 weeks, against 15 and 3.3 percent on placebo, at the cost of neutropenia and thrombocytopenia.\n\nOther cytopenias have fewer options: thrombopoietin agonists in trials, G-CSF for neutropenic infection, and iron chelation for transfusional iron overload (TELESTO). Allogeneic transplant is deferred until the disease progresses. Elritercept and other activin traps, oral hypomethylating agents at low dose, and drugs against the SF3B1 spliceosome defect are in trials, and IPSS-M is revealing that some patients labelled lower risk carry higher-risk mutations and should be treated accordingly.","asOf":"2026-09-17","wikipedia":"https://en.wikipedia.org/wiki/Myelodysplastic_syndrome","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Myelodysplastic_syndrome"},{"label":"NCCN Guidelines: Myelodysplastic Syndromes","url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1446"}],"tags":["subtype-page"],"related":[],"cancers":[],"sections":[],"technologies":["transfusion-support"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["anaemia","staging-systems","ageing-tissue-field-theory"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-commands-luspatercept-mds-lancet-2023","paper-imerge-imetelstat-mds-lancet-2024"],"journals":[],"dependsOn":[],"notes":[],"group":"haematologic","burden":"About two-thirds of people with myelodysplastic syndromes have lower-risk disease by IPSS-R; most are over 70, and anaemia rather than leukaemia is what shapes their lives, with many needing regular transfusions.","subtypes":["MDS with low blasts, IPSS-R very low or low","MDS with SF3B1 mutation and ring sideroblasts (luspatercept)","MDS with isolated del(5q) (lenalidomide)","Transfusion-dependent lower-risk MDS after erythropoietin failure (imetelstat, luspatercept)","Hypoplastic MDS (immunosuppression)","IPSS-R intermediate MDS reclassified by IPSS-M"],"biomarkers":["IPSS-R and IPSS-M scores","Serum erythropoietin level","Ring sideroblasts and SF3B1 mutation","del(5q)","Transfusion burden","Serum ferritin and iron overload","TP53 and other adverse mutations on IPSS-M"],"standardOfCare":[{"setting":"Asymptomatic, no transfusions","approach":"Observation with blood counts every three to six months; no treatment.","refs":["transfusion-support"],"guideline":{"version":"NCCN Guidelines: Myelodysplastic Syndromes","url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1446"}},{"setting":"Anaemia, first line","approach":"Luspatercept for ring-sideroblast or SF3B1-mutated disease and for transfusion-dependent patients (COMMANDS); erythropoiesis-stimulating agent where serum erythropoietin is below 500 U/L; lenalidomide for del(5q).","refs":["luspatercept","epoetin-alfa","darbepoetin-alfa","lenalidomide"],"guideline":{"version":"NCCN Guidelines: Myelodysplastic Syndromes","url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1446"}},{"setting":"Anaemia after erythropoietin or luspatercept failure","approach":"Imetelstat (IMerge); luspatercept if not yet used; low-dose hypomethylating agent; trials of elritercept and other agents.","refs":["imetelstat","luspatercept","azacitidine","nct06499285","nct05308264","nct06243458"],"guideline":{"version":"NCCN Guidelines: Myelodysplastic Syndromes","url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1446"}},{"setting":"Supportive care","approach":"Red cell transfusion to symptoms, iron chelation once ferritin is persistently high, G-CSF for recurrent neutropenic infection, platelet transfusion for bleeding.","refs":["transfusion-support","g-csf-growth-factors"],"guideline":{"version":"NCCN Guidelines: Myelodysplastic Syndromes","url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1446"}}],"stateOfArt":["Luspatercept is first-line treatment for transfusion-dependent anaemia after COMMANDS, and imetelstat gives a second line that works after erythropoietin fails.","IPSS-M has shifted treatment for many patients by finding high-risk mutations in disease that looked lower risk.","Transfusion independence, not survival, is the endpoint that has driven every approval."],"history":[{"year":1997,"title":"International Prognostic Scoring System for MDS","refs":["staging-systems"]},{"year":2005,"title":"Lenalidomide produces transfusion independence in del(5q) MDS","refs":["lenalidomide"]},{"year":2012,"title":"IPSS-R revised scoring system","refs":["staging-systems"]},{"year":2020,"title":"Luspatercept approved after MEDALIST","refs":["luspatercept"]},{"year":2022,"title":"IPSS-M adds mutations to risk scoring","refs":[]},{"year":2023,"title":"COMMANDS: luspatercept beats epoetin alfa in first line","refs":["luspatercept","epoetin-alfa"]},{"year":2024,"title":"Imetelstat approved after IMerge: the first telomerase inhibitor","refs":["imetelstat"]}],"pipeline":["luspatercept","imetelstat","nct06499285","nct05308264","nct06243458","nct05320198"],"openProblems":["No approved treatment for thrombocytopenia or neutropenia in lower-risk disease.","Whether early disease-modifying treatment changes the natural history rather than the transfusion count.","Iron overload management and quality of life are under-studied."],"parent":"mds"},"route":"/cancers/mds-lower-risk/","neighbours":{"technology":[{"id":"g-csf-growth-factors","kind":"technology","name":"Growth factors: G-CSF and febrile neutropenia prevention","route":"/technologies/g-csf-growth-factors/"},{"id":"transfusion-support","kind":"technology","name":"Transfusion support and anaemia management","route":"/technologies/transfusion-support/"}],"term":[{"id":"ageing-tissue-field-theory","kind":"term","name":"Ageing tissue and clonal fields: cancer as a disease of old tissue","route":"/terms/ageing-tissue-field-theory/"},{"id":"anaemia","kind":"term","name":"Anaemia","route":"/terms/anaemia/"},{"id":"staging-systems","kind":"term","name":"Disease-specific staging and risk systems (FIGO, Ann Arbor, IPI, R-ISS, ELN, IMDC)","route":"/terms/staging-systems/"}],"paper":[{"id":"paper-commands-luspatercept-mds-lancet-2023","kind":"paper","name":"COMMANDS: luspatercept versus epoetin alfa as first treatment for anaemia in lower-risk MDS needing transfusions","route":"/key-papers/paper-commands-luspatercept-mds-lancet-2023/"},{"id":"paper-imerge-imetelstat-mds-lancet-2024","kind":"paper","name":"IMerge: imetelstat, a telomerase inhibitor, for transfusion-dependent lower-risk MDS after erythropoietin has failed","route":"/key-papers/paper-imerge-imetelstat-mds-lancet-2024/"}],"drug":[{"id":"azacitidine","kind":"drug","name":"Azacitidine","route":"/drugs/azacitidine/"},{"id":"darbepoetin-alfa","kind":"drug","name":"Darbepoetin alfa","route":"/drugs/darbepoetin-alfa/"},{"id":"epoetin-alfa","kind":"drug","name":"Epoetin alfa","route":"/drugs/epoetin-alfa/"},{"id":"imetelstat","kind":"drug","name":"Imetelstat","route":"/drugs/imetelstat/"},{"id":"lenalidomide","kind":"drug","name":"Lenalidomide","route":"/drugs/lenalidomide/"},{"id":"luspatercept","kind":"drug","name":"Luspatercept","route":"/drugs/luspatercept/"}],"trial":[{"id":"nct06499285","kind":"trial","name":"A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular B","route":"/trials/nct06499285/"},{"id":"nct06243458","kind":"trial","name":"RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms","route":"/trials/nct06243458/"},{"id":"nct05320198","kind":"trial","name":"Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia","route":"/trials/nct05320198/"},{"id":"nct05308264","kind":"trial","name":"Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)","route":"/trials/nct05308264/"}],"cancer":[{"id":"mds","kind":"cancer","name":"Myelodysplastic syndromes / neoplasms (MDS)","route":"/cancers/mds/"}]}}